Correction: Omalizumab in severe allergic asthma (Annals of Internal Medicine (2011) 154 (573-582) DOI: 10.7326/0003-4819-154-9-201105030-00002);Omalizumab in severe allergic asthma inadequately controlled with standard therapy: A randomized trial

Annals of Internal Medicine

Volumn 154, Issue 9, 2011, Pages 573-582

  Hanania, Nicola A ^a   Alpan, Oral ^b   Hamilos, Daniel L ^c   Condemi, John J ^d   Reyes Rivera, Irmarie ^e   Zhu, Jin ^e   Rosen, Karin E ^e   Eisner, Mark D ^e   Wong, Dennis A ^e   Busse, William ^f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Section on Immunopathogenesis   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Allergy Asthma Immunology of Rochester   (United States)

^e GENENTECH INC   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CROMOGLYCATE DISODIUM; FLUTICASONE; FORMOTEROL; IMMUNOGLOBULIN E; MONTELUKAST; NEDOCROMIL; OMALIZUMAB; PLACEBO; PREDNISONE; SALBUTAMOL; SALMETEROL; ZAFIRLUKAST; ZILEUTON;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALLERGIC ASTHMA; ANAPHYLAXIS; ARTICLE; ASTHMA QUALITY OF LIFE QUESTIONNAIRE; BLEEDING; CANADA; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HEART ARREST; HUMAN; HYPERSENSITIVITY REACTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEOPLASM; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM; THROMBOCYTOPENIA; TREATMENT DURATION; UNITED STATES; URTICARIA;

EID: 79955751312     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/L19-0354     Document Type: Erratum

References (19)

1. National Heart, Lung, and Blood Institute, National Institutes of Health. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Washington, DC: U.S. Department of Health and Human Services; 2007.
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Bethesda, MD: National Institutes of Health; 1995. NIH publication no. 02-3659. Accessed at www.ginasthma.org on 15 March 2011.
3. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al; GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170:836-44.
4. Broder MS, Chang EY, Kamath T, Sapra S. Poor disease control among insured users of high-dose combination therapy for asthma. Allergy Asthma Proc. 2010;31:60-7.
5. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebocontrolled trial. Lancet. 2001;357:2007-11.
6. Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA, Stauffer JL, Philpot E, et al. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest. 2005;128: 1910-20.
7. American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med. 2007;175:235-42.
8. Walsh LJ, Wong CA, Oborne J, Cooper S, Lewis SA, Pringle M, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax. 2001;56:279-84.
9. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184-90.
10. Solér M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254-61.]
11. Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, et al; Omalizumab 011 International Study Group. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34:632-8.
12. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59:709-17.
13. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309-16.
14. Signorini DF, Leung O, Simes RJ, Beller E, Gebski VJ, Callaghan T. Dynamic balanced randomization for clinical trials. Stat Med. 1993;12:2343-50.
15. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest. 1999;115: 1265-70.
16. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis. 1993;147:832-8.
17. Chan IS, Zhang Z. Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics. 1999;55:1202-9.
18. Signorini DF. Sample size for Poisson regression. Biometrika. 1991;78:446-50.
19. Sampson HA, Muñoz Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117:391-7.